The Fund behind the ‘Biggest Private Exit Ever’ to Raise another €50M

05/07/2016 - 2 minutes

BioGeneration Ventures has had its first close of a new venture capital fund, ‘BioGeneration Capital Fund III’, for novel diagnostic, medtech and therapeutic biotechs in Europe. 

BioGeneration Ventures Capital Biotech fundBioGeneration Ventures (BGV) is based in Naarden (Netherlands) and manages funds investing in Netherlands, Belgium and Germany. 

Some of its biotech porfolio companies have included Dezima Pharma (acquired by Amgen from Forbion Partners), Mucosis (looking to use probiotics as needle-free vaccines) and argenx (a Belgian llama derived antibody biotech).

The new fund is looking for a total of 12 to 14 new enterprises in the Life Sciences field, with a stronger focus on the Netherlands. Companies working on diagnostics, innovative therapeutics and medtech are of particular interest.

Biogeneration Ventures Investment Fund Biotech 50

In addition to Dutch and UK based family offices, other existing investors such as Topfonds Gelderland (a fund managed by PPM Oost) and LEH Holding (holding company of Leiden University) joined the new fund.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

You might also be interested in the following:


Support Us

Become a Member